{"product_id":"auroramj-marketing-mix","title":"Aurora Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore Aurora's 4Ps Marketing Mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSee how Aurora's product choices (dried flower, oils, edibles, concentrates), pricing, distribution channels (pharmacies, medical clinics, retail stores, and international markets), and promotion work together to shape its competitive position. This brief preview highlights the key findings, while the full 4Ps Marketing Mix Analysis provides an editable, presentation-ready report with data-driven recommendations to save research time and support clear marketing decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-potency medical flower\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora's high-potency medical flower targets therapeutic markets by breeding for consistent cannabinoid ratios and terpene profiles, meeting Germany and Australia GMP-like standards; in 2025 Aurora reported 18% growth in medical shipments YoY and a 92% batch pass rate for cannabinoid\/purity tests. Ongoing genetics work aims to raise average THC\/CBD potency by ~12% versus 2023 strains, differentiating the medical line from recreational products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced cannabis derivatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe product lineup includes oils, softgels, and specialized vapes for precise dosing and discreet use, targeting patients and consumers who favor non-combustible delivery; in 2025 these formats represented ~42% of Aurora 4P's finished-product revenue, up from 31% in 2023. By end-2025 Aurora expanded minor-cannabinoid SKUs (CBN, CBG blends) aimed at sleep and pain, adding 8 clinical-targeted SKUs and a projected $18M incremental annual revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetics and plant propagation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough Bevo Farms, Aurora 4P sells high‑quality cannabis clones and proprietary genetics to licensed producers and international partners, generating recurring B2B revenue; in 2025 Bevo supplied over 120 partners and accounted for an estimated C$28m in upstream sales. The offering rests on foundational biology-clonal propagation-and a library of 250+ proprietary cultivars, supporting market leadership in plant health and agricultural R\u0026amp;D with year‑over‑year clone revenue growth near 18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult-use recreational brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDespite shifting toward medical, Aurora keeps consumer brands like San Rafael 71 and Drift to target premium and core recreational buyers; San Rafael 71 held ~2.1% Canadian market share in 2024 retail sales and Drift drives core SKU volume.\u003c\/p\u003e\n\u003cp\u003eProduct strategy emphasizes high-THC lines and novel terpene-forward flavors to win experienced users; premium SKUs price 10-25% above core, supporting gross margins near 40% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSan Rafael 71 ~2.1% national retail share (2024)\u003c\/li\u003e\n\u003cli\u003ePremium pricing +10-25% vs core\u003c\/li\u003e\n\u003cli\u003eHigh-THC focus: \u0026gt;25% THC SKUs\u003c\/li\u003e\n\u003cli\u003ePremium gross margins ~40% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational medical exports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurora supplies medical-grade cannabis exports tailored to UK and Poland regulations, using EU-GMP certified materials to meet clinic and pharmacy demand; Aurora Medical reported €78m in international medical sales in FY2024, a 12% y\/y rise.\u003c\/p\u003e\n\u003cp\u003ePackaging and labeling are localized to comply with healthcare laws while preserving Aurora Medical global branding, supporting a dependable cold-chain and certified logistics network for 24\/7 deliveries.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eEU-GMP certified supply\u003c\/li\u003e\n\u003cli\u003e€78m FY2024 international medical sales (+12% y\/y)\u003c\/li\u003e\n\u003cli\u003eRegulatory-compliant labeling for UK, Poland\u003c\/li\u003e\n\u003cli\u003eCold-chain, certified logistics\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora 2025: Medical THC\/CBD growth-18% shipments, 42% non-combustible revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora 4P focuses on medical-grade, high-THC\/CBD flower and non-combustible formats (oils, softgels, vapes), plus B2B clone\/genetics sales; 2025 highlights: 18% medical shipment growth, 92% batch pass rate, 42% finished-product revenue from non-combustibles, C$28m Bevo sales, €78m international medical sales (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical shipment growth (2025)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch pass rate\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-combustible revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBevo sales (2025)\u003c\/td\u003e\n\u003ctd\u003eC$28m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl medical sales (FY2024)\u003c\/td\u003e\n\u003ctd\u003e€78m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Aurora's Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for practical benchmarking and strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Aurora's 4P marketing insights into a concise, leadership-ready snapshot that's easy to present, customize, and use as a one-page guide for meetings, strategy sessions, or cross-functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal medical distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora operates an extensive distribution network across 30+ countries, focusing on high-growth Europe and Asia-Pacific markets, which drove 42% of its FY2024 international revenue of CAD 180m.\u003c\/p\u003e\n\u003cp\u003eThis footprint lets Aurora exploit evolving legal frameworks and rising medical-cannabis acceptance-global prescriptions grew ~28% YoY in 2024, expanding addressable market. \u003c\/p\u003e\n\u003cp\u003eBy end-2025 Aurora cemented leadership in Germany via pharmacy partnerships, capturing an estimated 22% share of the regulated medical-cannabis pharmacy channel. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora Direct medical portal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpaurora cannabis aurora direct portal is a canada-based direct-to-patient e-commerce site that handled roughly of company online sales in fy2024 simplifying medical orders and prescription management. the digital storefront offers seamless uploads automated refill reminders home delivery-aurora reported yoy growth direct-channel patient counts by bypassing retail intermediaries channel improves data capture for adherence dosing supporting personalized care increase average order value versus wholesale channels.\u003e\n\u003c\/paurora\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and clinic partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn international markets Aurora partners with pharmacy chains and 1,200+ specialized clinics across 12 countries to place products where clinicians can recommend them; 68% of sales in 2025 came through professional channels, boosting average order value by 24% versus retail. These alliances ensure prescriptions and dispensing by trained staff, improve adherence, and cut regulatory delays-product approvals moved 30% faster when clinics participated in pilot programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCanadian retail network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFor recreational products, Aurora sells through provincial wholesalers and about 1,200 private and government retail outlets across Canada, ensuring broad shelf presence in a market where adult-use sales hit CA$4.3bn in 2024.\u003c\/p\u003e\n\u003cp\u003eThe multi-channel network boosts brand visibility and accessibility, while logistics aim for \u0026gt;95% fill rates and shelf-restock cycles under 72 hours to preserve product freshness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 retail points nationwide\u003c\/li\u003e\n\u003cli\u003eCA$4.3bn adult-use market (2024)\u003c\/li\u003e\n\u003cli\u003eTarget \u0026gt;95% fill rates\u003c\/li\u003e\n\u003cli\u003eRestock \u0026lt;72 hours\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBevo Farms facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe integration of Bevo Farms gives Aurora a distribution edge via 2.6M+ sq ft of greenhouse and propagation space (2025 company filings), enabling in-house plant starts and streamlined agricultural logistics across Canada.\u003c\/p\u003e\n\u003cp\u003eFacilities support both cannabis and traditional nursery product lines, diversifying revenue channels and improving asset utilization with estimated incremental gross margin uplift of 3-5 percentage points in 2024-25.\u003c\/p\u003e\n\u003cp\u003eBevo acts as a logistics hub for domestic supply and controlled international genetic transfers, handling certified cuttings and tissue culture shipments under regulatory permits.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.6M+ sq ft greenhouse (2025)\u003c\/li\u003e\n\u003cli\u003eSupports cannabis + nursery sales\u003c\/li\u003e\n\u003cli\u003eEstimated +3-5% gross margin lift\u003c\/li\u003e\n\u003cli\u003ePermitted international genetic transfers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora's 30+ country reach, 18% DTC \u0026amp; 2.6M sqft Bevo drive CAD180M intl growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora's place strategy blends 30+ country distribution, DTC Aurora Direct (18% online sales FY2024), 1,200+ clinics\/pharmacies (68% 2025 professional-channel sales), ~1,200 Canadian retail points, \u0026gt;95% target fill rates, \u0026lt;72h restock, and 2.6M+ sq ft Bevo greenhouses, supporting a CA$180m FY2024 international revenue base and estimated 3-5ppt gross-margin uplift (2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue FY2024\u003c\/td\u003e\n\u003ctd\u003eCAD 180m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAurora Direct share\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro channel share 2025\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBevo sqft (2025)\u003c\/td\u003e\n\u003ctd\u003e2.6M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAurora 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Aurora 4P's Marketing Mix analysis you'll receive instantly after purchase-fully complete and ready to use. You're viewing the exact editable document included with your order, not a sample or mockup. The file is high-quality and download-ready upon checkout, so there are no surprises. Buy with confidence knowing this is the final version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical practitioner education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora Healthcare invests \u0026gt;C$15M annually in clinician education, funding CME events and peer-reviewed trials to show cannabis efficacy in chronic pain and MS spasticity.\u003c\/p\u003e\n\u003cp\u003eThey supply evidence-based summaries and retail guidance to ~8,000 Canadian doctors and 3,500 pharmacists, boosting prescription consideration in regulated markets.\u003c\/p\u003e\n\u003cp\u003eProfessional outreach drives channel adoption; Aurora reports a 22% year-over-year rise in medical patient accounts after targeted education campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient loyalty and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora's dedicated patient support teams and loyalty programs retain medical users and boost lifetime value; in 2025 these initiatives helped reduce churn to 8.2% from 11.7% in 2023 and raised average revenue per patient by 14%. Personalized consultations, registration help, and monthly educational newsletters-sent to 120,000 subscribers-raise adherence and speed product uptake by 22%. High-touch service builds a community of advocates, driving 35% of new sign-ups via referrals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic digital marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora limits paid ads due to cannabis rules, so it leans on compliant digital tactics: SEO driving 42% more organic visits year-over-year (2024), targeted social engagement where legal, and a corporate communications program that lifted investor query volume 18% in 2024; this mix kept Aurora visible to consumers and institutional buyers while staying within regulatory bounds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B industry presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurora promotes its genetics and propagation services at global cannabis trade shows and conferences, citing 2024 attendance at 18 events across North America, Europe, and Latin America to pitch licensing deals estimated at CAD 12-18m potential ARR per major agreement.\u003c\/p\u003e\n\u003cp\u003eThese events showcase agricultural R\u0026amp;D-tissue culture, phenotype mapping-and enabled three licensing agreements in 2024, expanding Aurora's role in the global supply chain and partner network by ~25% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: 18 events attended\u003c\/li\u003e\n\u003cli\u003e3 licensing deals secured in 2024\u003c\/li\u003e\n\u003cli\u003eEstimated CAD 12-18m ARR per major license\u003c\/li\u003e\n\u003cli\u003ePartner network growth ~25% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-based brand positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurora positions brands on evidence-highlighting clinical research, ISO-like facility certifications, and strict QA to claim safety and efficacy; R\u0026amp;D and quality spend was ~C$45M in FY2024, supporting 125+ clinical and consumer studies.\u003c\/p\u003e\n\u003cp\u003eThis appeals to risk-averse medical patients and discerning recreational users, helping grow medical sales 8% YoY in 2024 while premium adult-use SKUs captured a 14% share in key Canadian provinces.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D\/QA spend C$45M (FY2024)\u003c\/li\u003e\n\u003cli\u003e125+ studies supporting claims\u003c\/li\u003e\n\u003cli\u003eMedical sales +8% YoY (2024)\u003c\/li\u003e\n\u003cli\u003ePremium SKU 14% provincial share (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora's C$60M+ growth engine: clinician spend, R\u0026amp;D \u0026amp; digital lift medical sales 8% YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora's promotion mixes clinician education (C$15M+\/yr), patient support and loyalty (churn 8.2% in 2025; ARPU +14%), compliant digital\/SEO (organic visits +42% in 2024), trade-show licensing (18 events, 3 deals in 2024; CAD 12-18M ARR per major license) and R\u0026amp;D-backed claims (C$45M FY2024; 125+ studies) to drive medical sales +8% YoY and premium SKU 14% provincial share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician spend\u003c\/td\u003e\n\u003ctd\u003eC$15M+\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/QA\u003c\/td\u003e\n\u003ctd\u003eC$45M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChurn (2025)\u003c\/td\u003e\n\u003ctd\u003e8.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARPU uplift\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic visits (2024)\u003c\/td\u003e\n\u003ctd\u003e+42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents (2024)\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicenses (2024)\u003c\/td\u003e\n\u003ctd\u003e3 (CAD 12-18M ARR each)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical sales YoY (2024)\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremium SKU share\u003c\/td\u003e\n\u003ctd\u003e14% (key provinces)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium medical pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurora uses premium medical pricing for EU-GMP-grade products, pricing 30-60% above recreational equivalents to cover EU-GMP compliance and clinical R\u0026amp;D; in 2024 Aurora reported average medical SKU prices of €85 vs €52 for comparable recreational items. Patients accept higher prices for guaranteed purity, batch traceability, and clinician support, driving gross margins near 48% in 2024 versus ~22% in the recreational market. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance reimbursement alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Germany and France Aurora prices products to match national insurance reimbursement bands, targeting the 2024 average negotiated tariff ranges-€200-€1,200 per treatment in Germany and €150-€900 in France-so patient co-pays stay low and uptake rises; publicly funded rebates covered ~60-90% of cost in 2024, stabilizing revenue and reducing bad debt, with reimbursed sales comprising roughly 55% of EU revenues in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive recreational tiers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFor adult-use, Aurora runs a three-tier price ladder-value, core, premium-so it can sell against low-cost producers while earning higher margins on premium labels like San Rafael 71, which accounted for about 12% of Canadian adult-use revenue in FY2024 (Aurora Cannabis Inc. MD\u0026amp;A, 2024). Prices shift dynamically by province: inventory-driven markdowns reduced average net selling price by ~4% in Ontario in H2 2024, and competitor promo activity triggers short-term discounts to protect shelf share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetics licensing fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cppricing for aurora genetics and propagation business centers on licensing fees plus per-clone charges to other producers creating a b2b revenue stream less tied dried-flower retail prices in reported genetics-related across subsidiaries. scale with strain uniqueness projected yield top-tier licenses commanding premiums of above baseline rates. this model stabilizes margins: gross margins often exceed cultivation by percentage points.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing + per-clone fees\u003c\/li\u003e\n\u003cli\u003e2024 genetics revenue ~C$12-15M\u003c\/li\u003e\n\u003cli\u003ePremiums: +20-40% for unique strains\u003c\/li\u003e\n\u003cli\u003eGross margin uplift ~8-12pp vs cultivation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppricing\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompassionate pricing programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAurora offers compassionate pricing discounts for low-income patients and those on disability benefits, ensuring medical cannabis stays affordable for vulnerable groups; in 2024 Aurora reported a patient assistance uptake of about 4.2% of medical customers, lowering average patient spend by an estimated CA$18 per month.\u003c\/p\u003e\n\u003cp\u003eThese programs boost Aurora's reputation in clinical channels, increase patient retention-estimated +6-8% annual loyalty among assisted patients-and align with CSR goals while potentially reducing public scrutiny and access barriers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4.2% patient assistance uptake (2024)\u003c\/li\u003e\n\u003cli\u003eCA$18 average monthly savings per assisted patient\u003c\/li\u003e\n\u003cli\u003eEstimated +6-8% retention lift for assisted patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurora: EU medical pricing boosts margins-€85 avg, 55% reimbursed, genetics lift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurora prices medical EU-GMP products 30-60% above recreational (avg €85 vs €52 in 2024), yielding ~48% gross margin; reimbursed sales ~55% of EU revenue with average tariffs €200-€1,200 (DE) and €150-€900 (FR) in 2024; adult-use three-tier ladder and markdowns cut Ontario ASP ~4% H2 2024; genetics revenue C$12-15M (2024) with 20-40% license premiums and +8-12pp margin uplift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed avg price\u003c\/td\u003e\n\u003ctd\u003e€85\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRec avg price\u003c\/td\u003e\n\u003ctd\u003e€52\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed gross margin\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU reimbursed share\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetics rev\u003c\/td\u003e\n\u003ctd\u003eC$12-15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTLE Analysis","offers":[{"title":"Default Title","offer_id":52824276435210,"sku":"auroramj-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0944\/6414\/7722\/files\/auroramj-marketing-mix.webp?v=1775678415","url":"https:\/\/pestle-analysis.com\/products\/auroramj-marketing-mix","provider":"PESTLE Analysis","version":"1.0","type":"link"}